EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction

Diego Pilati, Eugene Kusi Agyei, Marwa Elkhashab, Elisabeth Fuchs, Ian Helstrup Nielsen, Tobias Wang Bjerg, Aina Karen Anthi, Anaïs Jiménez-Reinoso, Marie Beck Iversen, Layla Pohl, Ryo Narita, Susana Frago und 6 weitere

Journal of Biological Chemistry · 2025

DOI: 10.1016/j.jbc.2025.108508 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Diego Pilati und 17 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark. Hauptthemen laut MEDLINE: Receptors, Fc, Toll-Like Receptor 9, Histocompatibility Antigens Class I, Oligodeoxyribonucleotides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Norges Forskningsråd, Helse Sør-Øst RHF, Innovationsfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CpG-oligodeoxynucleotide (CpG ODN)-based Toll-like receptor (TLR) agonists are promising immunostimulatory adjuvants; however, low entry into TLR-rich cellular endosomal compartments and poor lymphatic accumulation limit clinical translation. In this work, we introduce a recombinant human serum albumin (rHA)-CpG ODN covalent conjugate (rHA-CpG) designed to exploit the neonatal Fc receptor (FcRn)-driven albumin cellular sorting pathway to maximize CpG delivery into TLR9-rich endosomes and accumulate in lymph nodes. Site-selective conjugation of CpG to albumin cysteine 34, distant from its main FcRn-binding interface, resulted in a retained pH-dependent human FcRn binding, and receptor-driven endosomal trafficking in a cellular recycling assay. Induction of tumor necrosis factor (TNF) secretion in THP-1 cells and interferon alpha (IFN-α) in human hematopoietic stem and progenitor cell (HSPC)-derived plasmacytoid dendritic cells (pDCs), in contrast, to a myeloid differentiation primary response 88 (MyD88) and TLR9 knockout cells, respectively, support TLR9-engagement. The rHA-CpG construct induced greater TNF-α than free CpG ODN in mouse RAW 264.7 cells, and in human peripheral blood mononuclear cells (PBMCs) and expansion of classical (CD14+CD16-) monocytes. Furthermore, greater accumulation of Cy5.5-labelled CpG in the inguinal (>3-fold) and axillary (>18-fold) lymph nodes was observed when conjugated to rHA compared to an unconjugated rHA/CpG mix following subcutaneous injection in mice. Moreover, increased LN accumulation of an rHA variant engineered with high FcRn-binding affinity supports an FcRn-driven mechanism. Demonstration of FcRn-mediated albumin targeting at intra- and extracellular sites provides the mechanistic basis for the potent immune induction observed using the novel rHA-CpG conjugate design class introduced in this work.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, FcToll-Like Receptor 9Histocompatibility Antigens Class IOligodeoxyribonucleotidesSerum Albumin, HumanHumansAnimalsMiceDendritic CellsTHP-1 CellsMice, Inbred C57BLEndosomes

Stichwörter der Autor:innen

CpG ODNFcRnTLR9albuminimmune adjuvantinnate immunitylymph nodes

Substanzen

Receptors, FcFc receptor, neonatalToll-Like Receptor 9Histocompatibility Antigens Class IOligodeoxyribonucleotidesTLR9 protein, humanCPG-oligonucleotideSerum Albumin, Human

Autor:innen und Institutionen

  • Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
  • Department of Biomedicine, Aarhus University, Aarhus C, Denmark.
  • Department of Immunology, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine and Department of Pharmacology, University of Oslo and Oslo University Hospital Rikshospitalet, Oslo, Norwa…
  • Immuno-Oncology and Immunotherapy Group, Biomedical Research Institute Hospital Universitario 12 de Octubre (imas12), Madrid, Spain; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12…
  • Leadartis, S.L., Madrid, Spain.
  • Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark. Electronic address: kenh@inano.au.dk.

Förderung

  • Norges Forskningsråd
  • Helse Sør-Øst RHF
  • Innovationsfonden
  • Danmarks Frie Forskningsfond
  • Independent Research Fund Denmark
  • Ministerio de Ciencia e Innovación

Zitieren

APA

Pilati, D., Agyei, E. K., Elkhashab, M., Fuchs, E., Nielsen, I. H., Bjerg, T. W., Anthi, A. K., Jiménez-Reinoso, A., Iversen, M. B., Pohl, L., Narita, R., Frago, S., Jakobsen, M. R., Andersen, J. T., Degn, S. E., Paludan, S. R., Alvarez-Vallina, L., & Howard, K. A. (2025). Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.108508

Vancouver

Pilati D, Agyei EK, Elkhashab M, Fuchs E, Nielsen IH, Bjerg TW, et al. Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.108508

BibTeX
@article{Pilati2025,
  author = {Pilati, Diego and Agyei, Eugene Kusi and Elkhashab, Marwa and Fuchs, Elisabeth and Nielsen, Ian Helstrup and Bjerg, Tobias Wang and Anthi, Aina Karen and Jiménez-Reinoso, Anaïs and Iversen, Marie Beck and Pohl, Layla and Narita, Ryo and Frago, Susana and Jakobsen, Martin R and Andersen, Jan Terje and Degn, Søren E and Paludan, Søren R and Alvarez-Vallina, Luis and Howard, Kenneth A},
  title = {Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  doi = {10.1016/j.jbc.2025.108508}
}
Kostenlos starten →